Related Experiment Video

Updated: Jul 7, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor

Kostyantyn Krysan1, Jay M Lee, Mariam Dohadwala

  • 1Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. KKrysan@mednet.ucla.edu

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|February 28, 2008
PubMed

Insights

Inflammation fuels lung tumor growth and resistance to therapies. Targeting inflammatory pathways and using biomarkers may improve treatment effectiveness for lung cancer patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Inflammation significantly contributes to lung tumor development and progression.
  • Inflammatory signaling pathways are implicated in promoting aggressive tumor phenotypes, metastasis, and therapeutic resistance.
  • Emerging research highlights the role of inflammation in resistance to targeted therapies, particularly epidermal growth factor receptor tyrosine kinase inhibitors.

Purpose of the Study:

  • To explore the contribution of inflammation to lung cancer progression.
  • To investigate the role of inflammatory mediators in resistance to epidermal growth factor receptor tyrosine kinase inhibitors.
  • To underscore the importance of combination therapies and biomarker selection for effective lung cancer treatment.

Main Methods:

  • Review of current literature on inflammation and lung cancer.
  • Analysis of signaling pathways involved in inflammation-induced resistance.
  • Discussion of therapeutic strategies targeting inflammatory mediators.

Main Results:

  • Inflammation promotes key processes in lung cancer, including epithelial to mesenchymal transition and metastasis.
  • Inflammatory mediators can induce resistance to targeted therapies like epidermal growth factor receptor tyrosine kinase inhibitors.
  • Combination therapies targeting both cancer cells and inflammatory pathways show promise.

Conclusions:

  • Targeting inflammation is a crucial strategy for overcoming lung cancer progression and therapeutic resistance.
  • Biomarker-driven patient selection will be essential for the success of combination therapies.
  • Further research into inflammatory pathways is needed to optimize lung cancer treatment.

More Related Videos

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

Induction and Analysis of Epithelial to Mesenchymal Transition10:37

Induction and Analysis of Epithelial to Mesenchymal Transition

Published on: August 27, 2013

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...